GH Research PLC Share Price & Technical Analysis
GHRS · $23.15 (+4.66%)
Healthcare / Biotechnology
$23.15
+4.66%
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II …
Price chart
Seasonality
May has 4 positive and 1 negative years (last 5 years shown)
13% return in May, 29% avg return in past 3 year May month.
72% return in 2026, 10% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 23% | -4% | -2% | 43% | 13% | – | – | – | – | – | – | – | 72% |
| 25 | 45% | -49% | 7% | -14% | 26% | 1% | 18% | -5% | 8% | 1% | 6% | -15% | 29% |
| 24 | 29% | 19% | 20% | 4% | 27% | -18% | 6% | -16% | -34% | 19% | 10% | -22% | 44% |
| 23 | -12% | 8% | -20% | 4% | 33% | 6% | 9% | -20% | -6% | -24% | -14% | -8% | -43% |
| 22 | -27% | -5% | 10% | -19% | -33% | 0% | 13% | 37% | -24% | -16% | 7% | -8% | -64% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Strong · Strong
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$1.44B
P/E ratio
—
52W high
$24.66
52W low
$10.96
Volume
2,99,855
Beta
1.28
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is GH Research PLC share price today?
- GH Research PLC (GHRS) last traded around $23.15 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does GHRS have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for GHRS. Download the app for real-time alerts.
- How can I analyze GH Research PLC stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.